2. Apoptosis Neuronal Signaling TGF-beta/Smad Stem Cell/Wnt Anti-infection
  3. TNF Receptor Cholinesterase (ChE) PKA Apoptosis Bacterial HIV Influenza Virus
  4. Linarin

Linarin  (Synonyms: Buddleoside; Linarine)

Cat. No.: HY-N0528 Purity: 98.02%
COA
SDS
Handling Instructions Technical Support

Linarin (Buddleoside) is an orally active and selective inhibitor of acetylcholinesterase (AChE). Linarin has many activities, such as anti-inflammatory, antioxidant, sleep aid and sedation, bone differentiation, anti-tumor, antibacterial and antiviral. Linarin can be used to study diseases such as the nervous system, osteoporosis and cancer.

For research use only. We do not sell to patients.

CAS No. : 480-36-4

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
20 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

Other Forms of Linarin:

Linarin Related Antibodies

Top Publications Citing Use of Products

    Linarin purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2026 Jan 8;19(1):111.  [Abstract]

    A549 cells were treated with the indicated doses of Linarin for 24 and 48 h to assess cell viability.

    Linarin purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2026 Jan 8;19(1):111.  [Abstract]

    A549 cells were treated with the indicated doses of Linarin (100, 200 μM) for 24 h, followed by EdU experiments to evaluate cell proliferation.

    Linarin purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2026 Jan 8;19(1):111.  [Abstract]

    Flow cytometric analysis of cell cycle in A549 cells treated with the indicated doses of Linarin (100, 200 μM) for 24 h. The percentages of cells in G0/G1, S, and G2/M phases are indicated within each panel.

    Linarin purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2026 Jan 8;19(1):111.  [Abstract]

    Representative Western blot images showing the expression of key cell cycle proteins (CDK1/4, CCNA2/B1 (Cyclin A2/B1), CHEK1/2 (Chk1/2)) in A549 cells treated with Linarin (100, 200 μM).

    Linarin purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2026 Jan 8;19(1):111.  [Abstract]

    SA-β-gal staining of H1299 cells treated with Linarin (100, 200 μM).

    View All TNF Receptor Isoform Specific Products:

    View All Isoforms
    TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

    View All Cholinesterase (ChE) Isoform Specific Products:

    View All Isoforms
    AChE BChE

    View All PKA Isoform Specific Products:

    View All Isoforms
    PKA PKAR PKACα

    View All HIV Isoform Specific Products:

    View All Isoforms
    HIV HIV-1 HIV-2

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Linarin (Buddleoside) is an orally active and selective inhibitor of acetylcholinesterase (AChE). Linarin has many activities, such as anti-inflammatory, antioxidant, sleep aid and sedation, bone differentiation, anti-tumor, antibacterial and antiviral. Linarin can be used to study diseases such as the nervous system, osteoporosis and cancer[1][2][3][4].

    IC50 & Target

    AChE

     

    Cellular Effect
    Cell Line Type Value Description References
    HT-22 EC50
    69.3 μM
    Compound: 8
    Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay
    Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay
    		[PMID: 32991171]
    RAW264.7 CC50
    > 100 μM
    Compound: 25
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33667099]
    RAW264.7 IC50
    10.02 μM
    Compound: 10
    Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method
    Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method
    		[PMID: 25176187]
    RAW264.7 IC50
    > 100 μM
    Compound: 25
    Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay
    Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay
    		[PMID: 33667099]
    In Vitro

    Linarin (25-100 μM; 24-72 h) inhibits the growth of human prostate cancer cells (LNCaP and DU145) and induces apoptosis[1].
    Linarin (0.1-10 μM; 6-21 days) activates the BMP-2/RUNX2 pathway through PKA signal transduction, and then induces osteogenic differentiation and mineralization of MC3T3-E1 osteoblasts[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Linarin Related Antibodies

    Western Blot Analysis[2]

    Cell Line: MC3T3-E1 cells
    Concentration: 0.1, 1 and 10 μM
    Incubation Time: 48 h
    Result: Dose-dependently increased BMP-2 and RUNX2 protein levels.

    Western Blot Analysis[2]

    Cell Line: MC3T3-E1 cells
    Concentration: 0.1, 1 and 10 μM
    Incubation Time: 6, 12, 24 and 48 h
    Result: Markedly stimulated PKA protein expression in a time- and dose-dependent manner.
    In Vivo

    Linarin (oral administration; 50-150 mg/kg; 8 weeks) can improve bone loss in ovariectomized mice[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Ovariectomy treated female C57/BL6 mice[2]
    Dosage: 50 and 150 mg/kg
    Administration: Oral administration (p.o.); 8 weeks
    Result: Dose‑dependently preserved the trabecular bone microarchitecture of ovariectomized mice.
    Slightly increased BMD compared to the control OVX group.
    Significantly decreased OVX-induced serum ALP and OCN levels.
    Molecular Weight

    592.55

    Formula

    C28H32O14
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(C=C(C1=CC=C(OC)C=C1)OC2=CC(O[C@@H]([C@@H]([C@@H](O)[C@@H]3O)O)O[C@@H]3CO[C@H](O[C@@H](C)[C@H](O)[C@H]4O)[C@@H]4O)=C5)C2=C5O
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 250 mg/mL (421.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.6876 mL 8.4381 mL 16.8762 mL
    5 mM 0.3375 mL 1.6876 mL 3.3752 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (3.51 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (3.51 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.6876 mL 8.4381 mL 16.8762 mL 42.1905 mL
    5 mM 0.3375 mL 1.6876 mL 3.3752 mL 8.4381 mL
    10 mM 0.1688 mL 0.8438 mL 1.6876 mL 4.2191 mL
    15 mM 0.1125 mL 0.5625 mL 1.1251 mL 2.8127 mL
    20 mM 0.0844 mL 0.4219 mL 0.8438 mL 2.1095 mL
    25 mM 0.0675 mL 0.3375 mL 0.6750 mL 1.6876 mL
    30 mM 0.0563 mL 0.2813 mL 0.5625 mL 1.4064 mL
    40 mM 0.0422 mL 0.2110 mL 0.4219 mL 1.0548 mL
    50 mM 0.0338 mL 0.1688 mL 0.3375 mL 0.8438 mL
    60 mM 0.0281 mL 0.1406 mL 0.2813 mL 0.7032 mL
    80 mM 0.0211 mL 0.1055 mL 0.2110 mL 0.5274 mL
    100 mM 0.0169 mL 0.0844 mL 0.1688 mL 0.4219 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Linarin Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Linarin480-36-4Buddleoside LinarineTNF ReceptorCholinesterase (ChE)PKAApoptosisBacterialHIVInfluenza VirusTumor Necrosis Factor ReceptorTNFRProtein kinase AHuman immunodeficiency virusLNCaPDU145MC3T3-E1Ovariectomized miceInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Linarin
    Cat. No.:
    HY-N0528
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.